Piperacillin-tazobactam plus netilmicin as empiric treatment for adult patients with acute leukemia, neutropenia, and fever: Single-center experience and retrospective comparison with piperacillin plus netilmicin

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 1, 1997, Pages 56-69

  Kern, Winfried V ^a   Maute, Beate ^a   Engel, Andreas ^a   Heil, Gerhard ^b   Kern, Peter ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

empiric therapy; fever; neutropenia; piperacillin tazobactam

Indexed keywords

CYTARABINE; NETILMICIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RASH; TREATMENT FAILURE;

EID: 0031027717     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80080-X     Document Type: Article

References (42)

1. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990;161:381-396.
2. Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis. 1993;17(Suppl 2):S378-S384.
3. Wade JC, Schimpff SC, Newman KA, et al. Piperacillin or ticarcillin plus amikacin. A double-blind comparison of empiric antibiotic therapy for febrile granulocytopenic patients. Am J Med. 1981;71:983-990.
4. Winston DJ, Ho WG, Young LS, et al. Piperacillin plus amikacin therapy versus carbenicillin plus amikacin therapy in febrile, granulocytopenic patients. Arch Intern Med. 1982; 142:1663-1666.
5. Calvo F, De Castro H, Brice P. Traitement des épisodes infectieux chez les malades neutropéniques par l'association pipéracilline et amikacine. Presse Med. 1986;15:2353-2357.
6. Mackie MJ, Reilly JT, Purohit S, Bartzokas CA. A randomized trial of Timentin and tobramycin versus piperacillin and tobramycin in febrile neutropenic patients. J Antimicrob Chemother. 1986;17(Suppl C):219-224.
7. Menichetti F, Del Favero A, Guerciolini R, et al. Empiric antimicrobial therapy in febrile granulocytopenic patients. Randomized prospective comparison of amikacin plus piperacillin with or without parenteral trimethoprim/sulfamethoxazole. Infection. 1986;14:261-267.
8. Barnes RA, Rogers TR. An evaluation of empirical antibiotic therapy in febrile neutropenic patients. Br J Haematol. 1987;66:137-140.
9. Norrby SR, Vandercam B, Louie T, et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: A prospective, randomized multi-clinic study. Scored J Infect Dis. 1987;52(Suppl):65-78.
10. Sage R, Hann I, Prentice HG, et al. A randomized trial of empirical antibiotic therapy with one of four β-lactam antibiotics in combination with netilmicin in febrile neutropenic patients. J Antimicrob Chemother. 1988;22:237-247.
11. Boughton BJ, Harris RI, Brown RM, et al. Gentamicin and low dose piperacillin in febrile neutropenic patients. J Antimicrob Chemother. 1989;24:45-51.
12. Herbrecht R, Damonte JC, Bergerat JP, et al. Piperacillin and netilmicin combination therapy for febrile episodes in neutropenic patients. Infection. 1990;18:310-313.
13. Novakova I, Donnelly P, De Pauw B. Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. Scand J Infect Dis. 1990;22:705-711.
14. Kelsey SM, Wood ME, Shaw E, et al. A comparative study of intravenous ciprofloxacin plus benzyl-penicillin versus netilmicin plus piperacillin for the empirical treatment of fever in the neutropenic host. J Antimicrob Chemother. 1990;25:149-157.
15. Feliu J, Artal A, Gonzalez Baron M, et al. Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer. Antimicrob Agents Chemother. 1992;36:2816-2820.
16. Kelsey SM, Weinhardt B, Collins PW, Newland AC. Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients. Eur J Clin Microbiol Infect Dis. 1992;11:509-514.
17. Leyland MJ, Bayston KF, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with hematological malignancies. J Antimicrob Chemother. 1992;30:843-854.
18. De Pauw BE, Deresinski SC, Feld R, et al, for the International Antimicrobial Study Group. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med. 1994;120:834-844.
19. Jacobs MR, Aronoff SC, Johenning S, et al. Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined β-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1986;29:980-985.
20. Cullmann W, Stieglitz M. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates. Chemotherapy. 1990;90:356-364.
21. Mehtar S, Drabu YJ, Blakemore PH. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime, and imipenem against multiple resistant gram-negative bacteria. J Antimicrob Chemother. 1990;25:915-919.
22. Strayer AH, Gilbert DH, Pivarnik P, et al. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994;38:2351-2356.
23. Kuck NA, Jacobus NV, Petersen PJ, et al. Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother. 1989;33:1964-1969.
24. Kern W, Kennedy SL, Sachdeva M, et al. Evaluation of piperacillin/tazobactam in experimental meningitis caused by a β-lactamase producing strain of K1-positive Escherichia coli. Antimicrob Agents Chemother. 1990;34:697-701.
25. Micozzi A, Nucci M, Venditti M, et al, Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis. 1993;12:1-8.
26. Marie JP, Vekhoff A, Cony-Makhoul P, et al, pour le Groupe d'étude des Aplasies Fé briles. Association pipéracilline/tazobactam plus amikacine versus ceftazidime plus amikacine chez les patients neutropéniques et fébriles: Etude multicentrique ouverte. Presse Med. 1995;24:397-401.
27. Cony-Makhoul P, Dufoir T, Maugein J, et al. Piperacillin-tazobactam for fever of unknown origin in severely neutropenic patients. In: Program and Abstracts of the 6th International Congress of Infectious Diseases; 1994; Prague. Abstract 1177.
28. Glasmacher A, Reeder K, Risse F, et al. Piperacillin-tazobactam and gentamicin as empiric antibiotic treatment for febrile neutropenic patients with leukemia. Onkologie. 1995;18(Suppl 2):196. Abstract.
29. Cometta A, Zinner S, De Bock R, et al, for the International Antimicrobial Therapy Cooperative Group of the EORTC. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1995;39:445-452.
30. Rozdzinski E, Feldkamp M, Schmeiser T, Kern W. Evaluation of the BACTEC high volume resin blood culture media in febrile neutropenic patients. Med Microbiol Letters. 1992;1:213-219.
31. Balows A, Hausler WJ Jr, Herrmann KL, et al, eds. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology; 1991.
32. DIN Deutsches Institut für Normung. Medizinische Mikrobiologie: Normen und weitere Unterlagen. Köln, Germany: Beuth Verlag; 1987.
33. SAS/STAT Guide for Personal Computers, Version 6 Edition. SAS Institute Inc., Cary, North Carolina; 1987.
34. Carratalá J, Fernández-Sevilla A, Tubau F, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20:557-560.
35. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. NEJM. 1994;330:1240-1241.
36. Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38:681-687.
37. Peña C, Albareda JM, Pallares R, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995;9:520-524.
38. The Meropenem Study Group of Leuven, London, and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother. 1995;36:185-200.
39. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 1995; 13:165-176.
40. Cometta A, Calandra T, Gaya H, et al, for the International Antimicrobial Therapy Cooperative Group of the EORTC, the GIMEMA Infection Program. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1996;40:1108-1115.
41. Kurrle E, Gaus W, Pflieger H, et al. Factors influencing the outcome of empiric antibiotic therapy in patients with granulocytopenia. Int J Exp Clin Chemother. 1989;2:167-176.
42. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother. 1993;31:585-598.